Tags : FabiFlu

Glenmark Report Results of FabiFlu (favipiravir) in P-III Clinical Study

Tuba Khan July 23, 2020

Shots: The P-III study assessing the efficacy and safety of Favipiravir + SSC vs SCC in 150 mild to moderate patients, randomized within a 48hour window of testing RT-PCR positive […]readmore

COVID-19 Pharma

Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to

Tuba Khan June 22, 2020

Shots: Glenmark has received manufacturing and marketing approval for its antiviral drug FabiFlu (favipiravir) to treat COVID-19 in India. The drug will be available as a prescribed therapy for INR […]readmore

Tags : FabiFlu

Glenmark Report Results of FabiFlu (favipiravir) in P-III Clinical Study

Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : FabiFlu

Glenmark Report Results of FabiFlu (favipiravir) in P-III Clinical Study

Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company